Amgen Wins Ruling on Patents for Kyprolis Cancer Drug
Source: Science Photo Library via Getty Images
This article is for subscribers only.
Amgen Inc. won a federal court ruling in a patent infringement lawsuit that could keep its Kyprolis injectable cancer treatment free from generic competition until the last of the patents’ expirations, in 2027.
U.S. District Judge Leonard Stark rejected Cipla Ltd.’s arguments that the three patents, owned by Amgen’s Onyx Therapeutics unit, are obvious variations of old ideas and shouldn’t have been issued. Cipla conceded infringement before the May 2019 bench trial, a common legal tactic that allowed it to focus on the validity of the patents.